SCHEMBL589632

SCHEMBL589632

NC(=O)c1cc(S(=O)(=O)c2ccccc2)ccc1N

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.56
HTR6 P50406 4/20 0.51
ALDH1A1 P00352 4/20 0.51
PKM P14618 1/20 0.51
PDE4B Q07343 4/20 0.48
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
SLC16A1 P53985 1/20 0.44
LMNA P02545 3/20 0.43
POLB P06746 2/20 0.43
CHUK O15111 1/20 0.43
ABCB1 P08183 1/20 0.42
ABCC1 P33527 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4953135 0.88 PKM (0.68) IKBKBHTR6ALDH1A1PKMMAPT
SCHEMBL8372993 0.88 HTR6 (0.53) HTR6ALDH1A1PKMMAPTGAA
SCHEMBL4953657 0.87 LMNA (0.62) IKBKBHTR6ALDH1A1PKMMAPT
SCHEMBL950448 0.82 HTR6 (0.74) HTR6ALDH1A1PKMMAPTGAA
SCHEMBL30166976 0.82 HTR6 (0.74) HTR6ALDH1A1PKMMAPTGAA
SCHEMBL715377 0.80 KDM4E (0.59) HTR6ALDH1A1PKMMAPTGAA
SCHEMBL11645023 0.80 MAPT (0.60) ALDH1A1PKMMAPTSMN1; SMN2CRHBP
SCHEMBL6272804 0.80 HTR6 (0.54) IKBKBHTR6ALDH1A1PKMMAPT
SCHEMBL9588158 0.80 MCL1 (0.50) IKBKBHTR6ALDH1A1PDE4BMAPT
SCHEMBL1806291 0.79 ALDH1A1 (0.53) IKBKBHTR6ALDH1A1PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101594862-B Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-11-25 CN disclosed
EP-2120932-B1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2014-07-09 EP disclosed
US-8114865-B2 Indazole derivatives as kinase inhibitors for the treatment of cancer NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-14 US disclosed
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-08-05 US disclosed
CN-101594862-A Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL (IT) 2009-12-02 CN disclosed
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 EP disclosed
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 WO disclosed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER MAP3K5, MAP3K19, MAP3K3 IKBKB 310/4885HTR6 3756/4885ALDH1A1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.